EN DE
Watch Medico Remedies Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Medico Remedies Limited (MEDICO) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Medico Remedies Limited stock ₹22.32, price ₹18.31, upside +21.9%, quality 50 out of 100. Rating: undervalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE630Y01024

MR Medico Remedies Limited logo Thin data Nov 13, 2026

Medico Remedies Limited

MEDICO · NSE

Solid company, but only slightly cheap (18% below fair value) and falling price: meets 1 of 3 rules.

Get notified free when this changes
Fair value ₹22.32 · Undervalued 
Low debt 
Ranks above peers (8/12) 
Last quarter vs. a year ago: revenue +81%, profit +36%. 
Quality 50/100 
Expensive Growth (revenue 5y +11.0 %/yr in INR) 
Thin margins · 5.8% net margin (TTM) 
Falling price (downtrend) 
Negative free cash flow 
Narrow moat 44/100
Thin data 
Watch Medico Remedies Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹96.70 ₹17.11 Fair Value ₹22.32 May 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.

How to read this chart

54‑month range ₹17.11 – ₹96.70 · fair‑value band ₹10.75 – ₹29.01 · the ₹18.31 price screens below the ₹22.32 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 13, 2026.

Follow Medico Remedies in your weekly email

Every Wednesday you see whether Medico Remedies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India.

Show moreShow less

The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics; antimalarials; dry syrups; ointments and creams; anti-diabetics; syrups; and miscellaneous products, as well as diuretics, antireterovirals, and steroidal preparations.

It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India.

Stock analysis

Medico Remedies Limited (MEDICO) currently trades at ₹18.31, while our model-based Fair Value estimate is ₹22.32, implying the stock looks roughly 18% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹33.90 per share, and 10 of the 15 models we run sit above the ₹18.31 price.

Bear case: the Asset-Based group reads lowest at ₹6.14, and 5 of the 15 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹10.75 (bear) to ₹29.01 (bull), the price of ₹18.31 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Medico Remedies Limited reported revenue of ₹2.1B in FY2026 versus ₹1.2B in FY2022, a compound +14.3%/yr. Reported net income was ₹131M in FY2026, compounding +28.5%/yr from FY2022.

Key figures

Market cap ₹1.5B (≈ $16.1M) Micro · P/E ratio 11.0 · P/S ratio 0.64 · EPS (TTM) ₹1.67 · Net margin 5.8% · Return on equity 19.0% · Return on assets (EBIT) 13.0% (5-year average) · Operating margin 3.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (medium confidence).

What moves the price

The share trades about 66% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 22%, MEDICO screens cheaper than that median.

Fair Value models

Bear ₹10.75 Fair Value ₹22.32 Bull ₹29.01
Price ₹18.31 · Upside +21.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹1.05 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings ₹6.35 ₹10.92 ₹18.16 74
EPV ₹8.56 ₹9.65 ₹10.56 74
ROIC Compounder ₹8.56 ₹10.22 ₹12.41 72
All 15 models by family
DCF Models
Owner Earnings ₹6.35 ₹10.92 ₹18.16 74
Earnings-Based
Graham-Dodd ₹10.75 ₹56.78 ₹78.60 63
Lynch FV ₹15.62 ₹22.32 ₹29.01 61
PEG = 1.0 ₹15.62 ₹22.32 ₹29.01 57
EPV ₹8.56 ₹9.65 ₹10.56 74
Multiples
P/E Multiple ₹26.08 ₹34.77 ₹43.46 63
P/S Multiple ₹20.15 ₹26.87 ₹33.58 58
P/B Multiple ₹30.68 ₹40.91 ₹51.14 55
EV/EBIT ₹19.32 ₹26.46 ₹33.59 66
EV/EBITDA ₹19.46 ₹26.64 ₹33.82 67
EV/Revenue ₹13.19 ₹19.74 ₹26.29 53
Asset-Based
NCAV (Graham) ₹4.06 ₹6.14 ₹7.68 54
Economic Profit
Residual Income ₹8.95 ₹11.57 ₹17.31 69
ROIC Compounder ₹8.56 ₹10.22 ₹12.41 72
Growth Earnings
Growth-Adj P/E ₹23.73 ₹33.90 ₹44.07 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 50/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 62
How much profit the company makes from its sales and capital
Quality Growth 55
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 69
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 80
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 56/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+36.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
Start year 2021 (pandemic). Over 10 years: +12.0% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.9%
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+29.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+29.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.38.3% vs 27.8%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 7%
2026 sits 58% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2021 (pandemic)

Watch MEDICO, get fair value alerts →

Compare Medico Remedies Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 50 · Below median
Fair Value upside +21.9% · Top 25%
Profitability
Return on equity (12 months) 19.0% · Top 25%
Return on assets 8.6% · Top 25%
Net margin (12 months) 5.8% · Below median
Operating margin (12 months) 3.7% · Below median
Growth and dividend
Revenue growth (quarter YoY) 81.4% · Top 25%
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 11.0× · Cheapest 25%
P/B 2.01× · Pricier than median
P/S (12 months) 0.64× · Cheapest 25%
EV/EBITDA 8.5× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)63 · sector 19
FUTURE (revenue growth)100 · sector 29
PAST (return on equity)76 · sector 26
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $83.82 $113.53 +35% vs MEDICO
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.02 ¥53.04 +10% vs MEDICO
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,868 ₹1,983 +6% vs MEDICO
Haleon plc HLN $9.17 $8.47 −8% vs MEDICO
Merck KGaA MRK €149.70 €108.83 −27% vs MEDICO
Galderma Group GALD CHF 191.00 CHF 112.30 −41% vs MEDICO
Takeda Pharmaceutical Company TAK $21.43 $11.20 −48% vs MEDICO
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs MEDICO
Teva Pharmaceutical Industries Limited TEVA $44.50 $20.74 −53% vs MEDICO
Divi's Laboratories Limited DIVISLAB ₹11,080 ₹1,567 −86% vs MEDICO

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medico Remedies Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Medico Remedies Limited Fair Value". https://www.fairvalue-calculator.com/stock/MEDICO

Frequently asked questions

Is Medico Remedies Limited (MEDICO) overvalued or undervalued?
As of Nov 13, 2026, our model estimates a fair value of ₹22.32 versus a price of ₹18.31, about +22% upside (undervalued).
What is the fair value of MEDICO?
Our model-based fair value for Medico Remedies Limited is ₹22.32 (as of Nov 13, 2026), built from audited fundamentals. The current price: ₹18.31.
What is the quality score of MEDICO?
Medico Remedies Limited has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medico Remedies Limited (MEDICO)?
Our model-based price target is the fair value of ₹22.32 (as of Nov 13, 2026) from 15 valuation models. Cautious scenario ₹10.75, optimistic scenario ₹29.01. It is a calculation from audited fundamentals, not an analyst target.
What is the Medico Remedies Limited stock forecast for 2026?
Our models put fair value at ₹22.32, about +22% upside versus a price of ₹18.31 (undervalued). Cautious scenario ₹10.75, optimistic scenario ₹29.01. The calculation is refreshed regularly with new filings.
What is the revenue of Medico Remedies Limited (MEDICO)?
Medico Remedies Limited reported trailing-twelve-month revenue of about ₹2.4B (latest available figure, as of Nov 13, 2026).
What is the intrinsic value of Medico Remedies Limited (MEDICO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medico Remedies Limited it is ₹22.32 per share (as of Nov 13, 2026), against a price of ₹18.31. It is the blended result of 15 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Medico Remedies Limited stock overvalued or undervalued in 2026?
As of Nov 13, 2026, MEDICO trades below its calculated fair value: price ₹18.31, fair value ₹22.32, a gap of about +22% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MEDICO?
No. The price is what the market pays today (₹18.31); the fair value is what the company's own numbers justify (₹22.32). For Medico Remedies Limited the two are ₹4.01 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medico Remedies Limited worth?
The market values Medico Remedies Limited at about ₹1.5B (market capitalisation, as of Nov 13, 2026). Per share that is ₹18.31; our models calculate a fair value of ₹22.32 per share.
What do the bullish and bearish scenarios say about MEDICO?
Our models span a range for Medico Remedies Limited: cautious scenario ₹10.75, base ₹22.32, optimistic ₹29.01 per share (as of Nov 13, 2026, price ₹18.31). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MEDICO?
Medico Remedies Limited trades at a price-to-earnings ratio of 11.0 (as of Nov 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹22.32 is built from several models across several years. Other multiples: P/B 2.0, P/S 0.6, EV/EBITDA 8.5.
How solid is the balance sheet of Medico Remedies Limited (MEDICO)?
Balance-sheet figures for Medico Remedies Limited (as of Nov 13, 2026): return on equity 19.0%, debt of 0.00 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is MEDICO from its 52-week high?
Medico Remedies Limited trades at ₹18.31, about 66% below its 52-week high of ₹54.24 and 2% above the low of ₹17.99 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹22.32 is for.
Which stocks are comparable to Medico Remedies Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medico Remedies Limited stock attractive at the current price?
The data as of Nov 13, 2026: price ₹18.31, calculated fair value ₹22.32 (+22%), Quality Score 50/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MEDICO calculated?
We run Medico Remedies Limited through 15 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹22.32 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Medico Remedies Limited currently trades 18% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medico Remedies Limited (MEDICO)?
The closing price on Nov 16, 2026 was ₹18.31. Our model-based fair value is ₹22.32, about +22% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medico Remedies Limited right now?
The model range is unusually wide (₹10.75 to ₹29.01). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (50/100) at a price below fair value, the discount is the argument here, not the business quality. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Medico Remedies Limited (MEDICO) come from?
Earnings per share at Medico Remedies Limited grew 27.5 % a year from 2015 to 2026. Broken into its drivers: revenue per share +12.6 %, EBIT margin +11.9 %, tax rate −0.4 %, residual (interest, one-offs) +1.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Medico Remedies Limited

How large is the market capitalisation of Medico Remedies Limited (MEDICO)?
The market capitalisation of Medico Remedies Limited is ₹1.5B (≈ $16.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medico Remedies Limited (MEDICO)?
The price-to-sales ratio of Medico Remedies Limited is 0.64 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medico Remedies Limited (MEDICO)?
Earnings per share at Medico Remedies Limited are ₹1.67 (price ÷ EPS = P/E 11.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medico Remedies Limited (MEDICO)?
The net margin of Medico Remedies Limited is 5.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medico Remedies Limited (MEDICO)?
The return on equity (ROE) of Medico Remedies Limited is 19.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medico Remedies Limited (MEDICO)?
On an EBIT basis the return on assets of Medico Remedies Limited is 13.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medico Remedies Limited (MEDICO)?
The operating margin of Medico Remedies Limited is 3.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medico Remedies Limited (MEDICO)?
Revenue at Medico Remedies Limited is growing 81.4% versus a year earlier (3y avg +13.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medico Remedies Limited (MEDICO)?
Earnings per share at Medico Remedies Limited are growing 36.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Medico Remedies Limited (MEDICO) generate?
The free cash flow of Medico Remedies Limited is −₹34.8M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Medico Remedies Limited (MEDICO) carry?
The net debt of Medico Remedies Limited is ₹173M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Medico Remedies Limited in the live analysis

One click puts Medico Remedies Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.